• I Ketut Gede Muliartha Laboratorium Biomedik Fakultas Kedokteran Universitas Brawijaya
  • Djanggan Sargowo Pascasarjana Universitas Brawijaya
  • Abdillah Iskandar Departemen Mikrobiologi Fakultas Kedokteran Universitas Mulawarman



Hyperhomocysteinemia appears to be an independent risk factor for coronary heart disease. Elevated levels
of  plasma  total  homocysteine  (tHcy)  was  caused  by  genetic  or  nutrient-related  disturbances  in  the
transsulfuration  or  remethylation  pathways  for  homocysteine  metabolism.  This  study  observed  premature
myocard  infarct  acute  patients  with  hyperhomocysteinemia.The  aim  of  the  research  was  to  determine
Cystarhionine-β  Synthase  and  Methylenetetrahydrofolate  Reductase  genes  mutations  in  premature  acute
myocard  infarct  patients  with  hyperhomocysteinemia.This  study  was  a  cross  sectional  study  in  premature
acute myocard infarct patients. Twenty three patients were examined for plasma total homocysteine, vitamin
B6, vitamin B12 folic acid and lipid profile. Total DNA isolated from patients with hyperhomocystememia and
normal  folic  acid,  vitamin  B6,  vitamin  B12  levels  and  lipid  profile.  Five  patients  were  assayed  for
Cystathionine-β  Synthase  and  gen  Methylenetetrahydrofolate  Reductase  genese  mutations  by  Polymerase
Chain  Reactions  (PCR).  Five  from  23  patients  (  21,7%  )  plasma  total


Download data is not yet available.



Evans RW, Shaten BJ, Hempel JD,Cutler JA, Kuller LH. Homocysteine and risk of cardiovascular disease in the Multiple Risk factor Interyention Trial. Arterioscier Thromb Vasc Biol.1997; 17:19A7-1953.

Chia-Lun Chao, Tsung-Li Kuo, Yuan-The Lee. Effects of methionine - induced Hyperhomoststeinemia on Endotheliumdependent Vasodilatation and Oxidative Status in healthy adults. Circulation. 2000; 101: 485-490.

Christen WG, Ajani UA , Glynn RJ, Hennekens CH. Blood levels of Homocysteine and increased risk of cardiovascular disease. Arch Intern Med. 2000; 160 : 422-434.

Clarke R and Collins R. Can dietry supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysten hypotesis of vascular disease. J of Cardiovascular Risk. 1998;5: 249- 255.

Michiel LB, Launer LJ, Lindemans J, Hoes AW, Hofman A, Witteman JC, et al. Homocystein and short-term Risk of Myocardial Infarction an Stroke in the Elderly. Arch Intern Med. 1999; 159 : 38-44.

De Jong SC, Stehouwer C, Berg VD, et al. Determinants of fasting and post methionine homocysteine levels in families predisposed to hyperhomocysteinemia and premature vascular disease. arterioscler Thromb Vasc Biol. 1999; 19:1316-1324.

Fallest PC, Koch D, Stein JH, Mcbride PE. Homocysteine:A New risk factor for atherosclerosis. American Academy of Family Physician, Vol. 56 : 6; 1997.

Folsom AR, Nieto FJ, Mc Govern et al. Prospective study of coronary heart disease incidence in relation to fasting homocysteine, related genetic polymorphism and B vitamins : the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1997; 98 :204-210.

Fonseca V, Guba SC, Fink LM. Hyperhomocysteinemia and the Endocrine System : Implication for Atheroslerosis and Thrombosis. Endocrin Rev. 1999; 20(5): 738.

Franco RF, Arauo AG, Guerreiro JF, Elton J, Zago MA. Analysis of the 677 C→T mutation of methyhetrahyrofolate reductase gene in different ethnic group. Thromb Haemost. 1998; 79: 119-121.

Frosst RF, Nieto J. Mc Govern PG, Tsa MY, Mallinow MR. Eckfeldt JH, es al. A candidate genetic risk factor for vascular disease : a common mutation in methyltetrahydrofolat reductase. Nat. Genet Vol.10;111-113.

Weech GN. Upchurch GR, Loscalzo J. Hyperhomocystein(e)mia and Atherotbrombotic. Ann NY Acad Sci. 1997; 811: A8-58.

Vladisav Stefanovic. Hyperhomocysteinemia : Arisk factor for Cardiovascular Disease. The Scientific Journ FACTA UNEYERSITATIS. 2000; Vol 7; 1; 7-10.

Lievers KJ, Boers GH, Verhoeg P, den Heijer M, Kluijtmans LA, van der Put NM, et al. A second common variant in the methyltetrahidrofolat reductase (MTHFR) gens and its relationship to MTHFR enzym activity, homocysteine, and cardiovascular disease risk. J Mol Med. 2001; 79(9):52.2-528.

Weisberg IS, Jacques PF, Selhub J, et al. The 1298A→C polymorphism in methylenetetrahydrofolate reducrase(MTHFR): in Vitro expression and association with homocysteine. Atherosclerosis.2001; 156(2): 409-415.

Brouwer DJ, Erik W, Reijngoud D, Van Dormal JJ, Muskiet F. Plasma folic acid cutoff value, derived from its relationship with homocysteine. Clinical Chemistry. 1998;44,7:1545-1550.

Robinson K, Arheart K, Refsum H , et al. Low circulating folate and vitamin B6 concentrations risk factors for stroke, peripheral vascular disease, and coronary artery disease. Circulation. 1998; 97: 437-443.

Jing Ma, Stampfer Ml, Hennekens CH, et al. Methylnetetrthydrofolate Reductase Polymorphism, Plasma Folate, Homocysteine and Risk of Myocardial Infarction in US Physicians. 1996; 94: 2410-2416.

Brattstrom L, Willcken D, John Ohrvik, et al. 1998. Common Methyltetrahydrofolat Reductase Gene Mutation Leads to Hyperhomocystinemia but not vascular Disease.Circulation. 1998; 98: 2520 - 2526.

Tsai MY. Laboratory assessment of mild hyperhomocysteinemia as an independent risk factor for occlusive vascular disease. Clin Chem. 1996; 42: 492-493.

Kanani PM, Sinkey CA, Browning RL, Allaman M, Howard RK, Haynes WG. Role of oxidant stress in endothelial dysfunction produced by experimental hiperhomocyst(e)inemia in humans. Circulation 1999; 100: 1161-1168.






Research Article

Most read articles by the same author(s)